Shouldn’t you be trying something like this to help your heart’s arteries?

Consider Niaspan. For patients with high cholesterol and plaque in the arteries of the heart, Niaspan, along with diet and another cholesterol medication (colestipol), is FDA-approved to not only slow down plaque buildup, but also help reduce the plaque that’s already ther

Ask your doctor if Niaspan is right for you.
Tear our this ad. Take it to your doctor. Ask if you should be doing something about plaque.

To view the ad, click here

Brand name: Niaspan
Generic name/category: Niacin, Hypolipidemic agents
Company: Abbott
Country/Market: USA, North America
Indication(s)/use: lower high cholesterol and reduce plaque
Target: Consumers (DTC)
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Heart-healthy Living – Fall 2009

“i didn’t realize there was more to the picture than just bad cholesterol.”

It’s important to know that there are three main parts of cholesterol. If your triglycerides (fat in the blood) are high or your good cholesterol is too low, ask your doctor about Trilipix.

If you cannot afford your medication, contact www.pparx.org or call the toll-free phone number (1-888-4PPA-NOW) for assistance.

For more information, visit trilipix.com or call 1.866.665.8003.

Brand name: Trilipix
Generic name/category: Fenofibrate
Company: Abbott
Country/Market: USA, North America
Indication(s)/use: Reduction or low-density lipoprotein (LDL), Very low-density lipoprotein (VLDL) and triglycerides and increasing HDL (high-density lipoprotein)
Target: Healthcare Professionals (HCP)
Tagline: There’s more to cholesterol. Get the picture.
Publication: US News And World Report July 2009

To see all of the ads from this campaign, click here
To see all of this brand’s ads on AdPharm, click here

For infants at high risk RSV prevention is never premature.
Help protect them during RSV season.
Synagis is a monoclonal antibody proven to help prevent serious RSV infection in high-risk infants

Palivizumab (brand name Synagis) is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of Respiratory Syncytial Virus (RSV) infections. It is recommended for certain infants that are high-risk (because of prematurity or other medical problems), see below.

Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of the Respiratory Syncytial Virus (RSV). In two Phase III clinical trials in the pediatric population, Palivizumab reduced the risk of hospitalization due to RSV infection by 55% and 45%. Palivizumab is dosed once a month via intramuscular (IM) injection, to be administered throughout the duration of the RSV season.

Palivizumab targets the fusion protein of RSV, inhibiting its entry into the cell and thereby preventing infection. – Wikipedia

Paediatrics and Child health April 2009

In moderate to severe Crohn’s disease, demonstrated to sustain power, sustain remission.

Adalimumab (brand name HUMIRA) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFa, preventing it from activating TNF receptors; adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. TNFa inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. As of 2008 adalimumab has been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

Humira (brand name is an abbreviation of "Human Monoclonal Antibody in Rheumatoid Arthritis") is marketed in both preloaded 0.8 ml syringes and also in preloaded pen devices (called Humira Pen), both injected subcutaneously, typically by the patient at home. It cannot be administered orally, because the digestive system would destroy the drug.

Humira’s manufacturer is Abbott Laboratories. – Wikipedia

CMAJ April 2009

More Humira ads on AdPharm